ProtoKinetix, Incorporated (PKTX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.52: the stock has moved about 48% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProtoKinetix, Incorporated (PKTX) trades at $0.0002. ProtoKinetix, Incorporated is a biotechnology company focused on the research and development of anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for PKTX: PKTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ProtoKinetix, Incorporated (PKTX) Healthcare & Pipeline Overview
ProtoKinetix, Incorporated is a research and development stage biotechnology firm specializing in anti-freeze and anti-aging glycoproteins for healthcare applications, particularly dry-eye disease treatment. Operating in the competitive biotechnology sector, the company collaborates with the University of British Columbia to advance its research and development efforts.
What Is the Investment Thesis for PKTX?
ProtoKinetix, Incorporated presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's focus on AFGPs and AAGPs offers potential in the healthcare sector, particularly for dry-eye disease treatments. However, the company's negative profit margin of -772.8% and negative gross margin of -28.4% indicate significant financial challenges. Key value drivers include successful clinical trials and commercialization of its AAGP technology. Growth catalysts depend on securing additional funding and partnerships. Potential risks include regulatory hurdles, competition from established pharmaceutical companies, and the inherent uncertainty of biotechnology research.
Based on FMP financials and quantitative analysis
PKTX Key Highlights
Market capitalization of $0.00B reflects the company's early stage and speculative nature.
- P/E ratio of -7.03 indicates the company is not currently profitable.
- Profit margin of -772.8% highlights significant losses relative to revenue.
- Gross margin of -28.4% suggests challenges in controlling production costs.
- Beta of 0.52 indicates lower volatility compared to the overall market.
Who Are PKTX's Competitors?
PKTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | 0.00% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $16.90 | -1.05% | $90.6M | 83 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.55 | +1.34% | $186M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.61 | -1.75% | $202M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.68 | -3.94% | $213M | 68 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | 0.00% | $218M | 73 5-pillar |
| QTTB Q32 Bio Inc. | $8.37 | +1.70% | $249M | 67 5-pillar |
| CRMD CorMedix Inc. | $7.26 | +0.97% | $571M | 94 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PKTX's Key Strengths?
Proprietary AAGP/AFGP technology.
- Collaboration with the University of British Columbia.
- Potential for novel dry-eye disease treatment.
- Focus on a growing market segment within healthcare.
What Are PKTX's Weaknesses?
Research and development stage company with no current revenue.
- High operating losses and negative profit margin.
- Reliance on external funding for continued operations.
- OTC market listing indicates higher risk and lower liquidity.
What Are the Key Risks for PKTX?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to secure additional funding could halt research and development activities and threaten the company's survival.
- Negative results from clinical trials could undermine the company's prospects and lead to a decline in its stock price.
- Competition from established pharmaceutical companies with greater resources and expertise.
- Regulatory hurdles and lengthy approval processes for new drug therapies.
- The inherent uncertainty of research and development outcomes in the biotechnology industry.
What Are PKTX's Competitive Advantages?
- Proprietary glycoprotein technology (AFGPs and AAGPs).
- Collaboration research agreement with the University of British Columbia.
- Potential for novel treatments in the dry-eye disease market.
What Does PKTX Do?
ProtoKinetix, Incorporated, established in 1999 and based in Marietta, Ohio, is a biotechnology company in the research and development phase. Originally incorporated as RJV Network, Inc., the company rebranded in July 2003 to reflect its focus on scientific medical research of anti-freeze glycoproteins (AFGPs), also known as anti-aging glycoproteins (AAGPs). These glycoproteins are being explored for their potential commercial applications, primarily in healthcare solutions. The company's core focus is on developing AAGP-based treatments, with a specific emphasis on addressing dry-eye diseases. ProtoKinetix operates through research collaborations, including an agreement with the University of British Columbia, to further its scientific advancements. ProtoKinetix is dedicated to advancing its research and development efforts in the biotechnology space, specifically targeting healthcare solutions through its unique glycoprotein technology.
What Products and Services Does PKTX Offer?
- Conducts scientific medical research on anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs).
- Develops AFGPs for commercial applications in health care solutions.
- Focuses on developing AAGP to treat dry-eye diseases.
- Collaborates with the University of British Columbia for research purposes.
- Aims to create innovative healthcare solutions based on its glycoprotein technology.
How Does PKTX Make Money?
- Focuses on research and development of AAGPs and AFGPs.
- Seeks to commercialize its glycoprotein technology through healthcare applications.
- Explores partnerships and collaborations to fund and accelerate development.
What Industry Does PKTX Operate In?
ProtoKinetix operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for dry-eye disease treatments is growing, driven by an aging population and increased screen time. Competitors include both established pharmaceutical companies and other biotechnology firms developing novel therapies. ProtoKinetix's success depends on its ability to differentiate its AAGP technology and navigate the complex regulatory landscape.
Who Are PKTX's Key Customers?
- Future patients suffering from dry-eye diseases.
- Potential pharmaceutical partners interested in licensing or acquiring their technology.
- Healthcare providers seeking innovative treatment options.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
ProtoKinetix, Incorporated's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
ProtoKinetix, Incorporated operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dalton, US. The company is led by CEO Michael Richard Guzzetta. PKTX has traded publicly since 2002.
Insider Activity
12 transactions · 12 purchases, 0 sales, 0 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
PKTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
PKTX Latest News
No recent news available for PKTX.
PKTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PKTX.
Price Targets
Wall Street price target analysis for PKTX.
PKTX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PKTX; grades run from A+ (80-100) to F (below 30).
Leadership: Michael Richard Guzzetta
CEO
Michael Richard Guzzetta serves as the CEO of ProtoKinetix, Incorporated. His leadership is focused on guiding the company's research and development efforts in the biotechnology sector, specifically related to anti-freeze and anti-aging glycoproteins.
Track Record: Due to limited information, it's challenging to assess Michael Richard Guzzetta's specific achievements and strategic decisions at ProtoKinetix. His tenure involves navigating the challenges of a research and development stage company, focusing on scientific advancements and seeking potential commercial applications for the company's technology.
PKTX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ProtoKinetix may not meet the minimum financial standards or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited operating history, are thinly traded, or may be experiencing financial difficulties. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Difficulty in obtaining reliable financial information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's intellectual property portfolio and competitive landscape.
- Evaluate the company's funding sources and cash runway.
- Understand the company's business model and revenue potential.
- Consult with a qualified financial advisor.
- Be aware of the risks associated with OTC investments.
- Collaboration research agreement with the University of British Columbia.
- Focus on scientific medical research of AFGPs/AAGPs.
- Efforts to develop treatments for dry-eye diseases.
- Company has been in operation since 1999.
What Investors Ask About ProtoKinetix, Incorporated (PKTX) — Healthcare
What do analysts say about PKTX stock?
As a thinly traded OTC stock with limited analyst coverage, there is no readily available analyst consensus on PKTX. The company's valuation is speculative, driven by the potential of its AAGP technology.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may not be fully up-to-date.